Reshaped human antibody. These sequences do not exhibit type-specific sequences.

Reshaped human antibody. As the major part of the reconstituted antibody derives from a human antibody and antigenicity of the CDR is low, this antibody has a low antigenicity against the human body, thus being expected to be applicable for medical therapy. DEMUTH, MICHELLE LELAND,ANDGERALD R. . One patient had lymphadenopathy which also resolved. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSV- induced disease It is therefore possible to compare directly the chimeric and reshaped human antibodies in antigen-binding assays that employ anti-human constant region antibody-enzyme conjugates for detection. Our results show that both approaches for the design of reshaped human antibodies can be used for successful humanization. 5 beta, therefore, has potential as a therapeutic agent for the prevention and treatment of acquired immunodeficiency syndrome (AI … reshaped human antibody variable regionsare linked to human antibody constant regions. In antigen-binding assays and competition-binding assays, the reshaped human antibodies were compared with mouse 425 antibody and to chimeric 425 antibody. Mar 28, 2024 · reshaped human antibody variable regionsare linked to human antibody constant regions. A reshaped antibody comprising: (A) L chains comprising: (1) a human C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of a mouse monoclonal antibody; and (B) H chains comprising: (1) a The present invention relates to variable regions (V region) of a mouse monoclonal antibody to the human interleukin-6 receptor (IL-6R), human/mouse chimeric antibody to the human IL-6R, and reshaped human antibody comprising a human antibody wherein the complementarity determining regions (CDRS) of the human light chain (L chain) V region and of the human heavy chain (H chain) V region are PRECLINICAL PHARMACOKINETIC EVALUATION OFTHERESPIRATORY SYNCYTIAL VIRUS-SPECIFIC RESHAPED HUMAN MONOCLONAL ANTIBODY RSHZI9 CHARLES B. The present invention relates to reshaped human anti-HM 1. The molecules of the invention are useful for diagnostics, prophylaxis and treatment of allergy. Authority ZA South Africa Prior art keywords human reshaped interleukin antibody human antibody Prior art date 1993-05-31 Application number ZA943778A Other languages English (en) Inventor Masayuki Tsuchiya Koh Sato Yuichi Hirata Original Assignee Chugai Seiyaku Kagushiki Kaish reshaped human antibody variable regionsare linked to human antibody constant regions. The reshapedantibody has the following elements: a human lchain C region or a human lchain FR and an lchain CDR from a mouse monoclonal antibody against human IL-8 and a human hchain C region or a human hchain FR and an hchain CDR of mouse The best images were obtained at 24 and 48 h after the [123I]- and [111In]H17E2, respectively. Reshaped human MAb RSHZ19, which is specific for the surface fusion protein of respiratory syncytial virus (RSV) is in clinical development for the prevention and treatment of RSV-induced disease in human infants. The resulting reshaped human antibody, HuHMFG1, showed no difference in relative affinity for its antig … reshaped human antibody variable regionsare linked to human antibody constant regions. A—HUMAN NECESSITIES A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00—Medicinal preparations containing peptides reshaped human antibody variable regionsare linked to human antibody constant regions. , of cerebral tumor, containing plural complementarity determining regions and framework regions having a specific amino acid sequence and having low antigenicity. While reshaped anti-junin antibodies showed similar or superior biliding to virus compared to the progenitor mouse antibody, the reshaped antibodies appeared to be 10-fold " less effective in virus neutralization. A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. Antibody humanization and CDR Grafting. Following transient expression in cos cells, all of the constructions were capable of producing humanlike antibody. (A) Mouse/human chimeric antibodies retain the entire Fv regions from the murine antibody (66% human). 24 antibody having: (A) an L chain having (1) the C region of a human L chain, and (2) the V region of an L chain having the FR of a human L chain and the CDR of the L chain of a mouse anti-HM 1. It has been humanized by CDR-grafting for therapeutic use. In contrast, it has proven relatively straightforward to make many mouse and rat antibodies to human tissue antigens. Mar 24, 1988 · A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. Similar Documents Publication Publication Date Title TW526206B 2003-04-01 Reshaped human antibody to human medulloblastoma cells TW458985B 2001-10-11 Reconstructed human antibody against human interleukin-6 AU707440B2 1999-07-08 Antibodies against E-selectin AU2013329381B2 2018-09-06 Antibodies recognizing alpha-synuclein A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. A human antibody with milk mucin specificity was obtained by transferring the complementarity determining regions (CDR) of the mouse antibody HMFG1 onto carefully selected human framework regions. HEPBURN, JAMES J. A preclinical evaluation of RSHZ19, a respiratory syncytial virus-specific reshaped human monoclonal antibody (IgG1 framework), has included pharmacokinetic studies in rats, adult cynomolgus macaques, and infant baboons after intravenous (iv), subcutaneous, or intramuscular (im) administration. Reshaped anti-Junin and reshaped anti-vaccinia antibodies were produced and tested for binding and virus neutralization. , of a chimera antibody useful for treatment, diagnosis, etc. PURPOSE: To obtain an L chain variable region of an antibody against a human medulloblastoma cell useful for preparation, etc. Since major portions of the reshaped human antibody is derived from a human antibody and CDRs has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to human, and therefore is promising for the use in medical therapy. HERZYK, SANDRA G. In addition, the present invention relates to a single chain Fv composed by linking an H chain V region of a reshaped human antibody to human medulloblastoma cells and an L chain V region of said antibody. The present invention further provides vectors, especially expression vectors comprising said DNA, and host cells transformed or transfected with said vector. RHODES A reshaped human anti-HM 1. These effects were achieved without A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. 24 antibodies, can solve the problems of limited human medical therapeutic value of mouse monoclonal antibodies, no effective therapeutic agents that can lead to remission of myeloma and prolong the survival period of patients with myeloma, and no effective therapeutic agents to achieve One version of reshaped human 0. Jan 1, 1993 · raising human antibody responses to autologous tissue antigens. reshaped human antibody variable regionsare linked to human antibody constant regions. Moreover, the present invention relates to a genetic engineering process for reshaped human antibody variable regionsare linked to human antibody constant regions. None of these patients developed human anti-mouse antibody responses (HAMA). In order to further reduce the mouse sequence of hAb, reshaped antibodies (RAb) have been constructed on the basis of chimeric antibodies in recent years. 24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H One version of reshaped human 0. the portion derived from the non-human protein sequence of a reshaped human antibodyis only the CDRs and an extremely small portion of the framework (FR). In the design of reshaped human AUK12-20 VL region, the human framework regions (FRs) from the human Bence-Jones protein REI were used. Benefits of technology [0019] Thus, the present invention relates to a reshaped human antibody of a mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Afte … Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6. A—HUMAN NECESSITIES A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00—Medicinal preparations containing peptides Mouse monoclonal antibody (mAb) 0. 24 antibody comprising:[0002] Human B cells go through a variety of processes that are classified based on the kind of surface antigens being expressed, and finally mature into antibody-producing plasma cells. The present invention discloses a reshaped human antibody against human IL-8 comprising: (A) L chains each comprising: (1) a human L chain C region; and, (2) an L chain V region comprising a human L chain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and, (B) H chains each comprising: (1) a human H chain C region; and, (2) an H chain V region comprising a human H In antigen-binding assays and competition-binding assays, the reshaped human antibodies were compared with mouse 425 antibody and to chimeric 425 antibody. DAVIS,TIMOTHY W. A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. At the final stage of their differentiation, B cells, on one hand, acquire the ability of producing cytoplasmic immunoglobulins and, on the other, B Dec 17, 1988 · A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. CDRscomprise hyper-variable protein sequences. HART, DANUTA J. 24 antibodies and chimeric anti-HM 1. 5 beta binds to the envelope protein gp120 of human immunodeficiency virus (HIV) and neutralizes infection by HIV in vitro. A reshaped human anti-HM 1. URBANSKI, DEBORAH C. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. In addition, the present invention provides a human / mouse chimeric antibody useful during the course of producing said reshaped human antibody. (Shaded ovals: murine sequences; blank ovals: human sequences; black lines across Mar 24, 1988 · A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against An immunosuppressive rat antibody (Campath-9) against human CD4 has been reshaped for use in the management of autoimmunity and the prevention of graft rejection. The current studies profile lung virus clearance and evaluate lung histopathology in M … Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses. 24 antibody comprising: (A) an L chain comprising (1) the C region of a human L chain, and (2) the V region of an L chain comprising the FR a human antibody and chimeric antihm technology, applied in the field of reshaped human chimeric antihm 1 . CDRscomplementarity determining regions these reshaped human antibody variable regionsare linked to human antibody constant regions. RAb refers to the use of genetic engineering technology to replace the complementarity-determining region (CDR) sequence in the variable (V) region of human antibodies with the CDR sequence However, an alternative route to obtain human MAbs was established by Dr G. Abstract Mouse monoclonal antibody AUK12-20 binds to human IL-6 receptor and inhibits IL-6 functions. , and achieve less immunogenic A reshaped human antibody or reshaped human antibody fragment having specificity for human polymorphic epithelial mucin (PEM) is produced by transferring the complementarity determining regions (CDRs) from a murine anti-HMFG hybridoma cell line HMFG1 into a human antibody variable region framework. the portion derived A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. At the final stage of their differentiation, B cells, on one hand, acquire the ability of producing cytoplasmic immunoglobulins and, on the other, B Oct 12, 1999 · A reshaped human antibody is characterized as having the same binding affinity for IL-8 as a chimeric antibody but with low immunogenicity in comparison. The reshaped molecule can be used in the treatment or diagnosis of cancer. Two different forms of the reshaped antibody were produced that derive their heavy A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against human lymphocytes. KWOK, TIMOTHY K. 24 antibodies, genes encoding them, methods for producing said antibodies, and the use of said antibodies. Mouse mAb 0. The reshaped antibody has the following elements: a human L chain C region or a human L chain FR and an L chain CDR from a mouse monoclonal antibody against human IL-8 and a human H chain C region or a human H chain FR and an H chain CDR of The present invention discloses a reshaped human antibody against human IL-8 comprising: (A) L chains each comprising: (1) a human L chain C region; and, (2) an L chain V region comprising a human L chain FR, and an L chain CDR of mouse monoclonal antibody against human IL-8; and, (B) H chains each comprising: (1) a human H chain C region; and, (2) an H chain V region comprising a human H Feb 20, 1996 · Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6. 24 monoclonal antibody; and (B) an H chain having (1) the C region of a human H chain, and (2) the V region of an H chain having the FR of a human H reshaped human antibody variable regionsare linked to human antibody constant regions. The reshaped human antibody is as effective as the rat antibody in complement and is more effective in cell-mediated lysis of human lymphocytes. A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRS) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a A—HUMAN NECESSITIES A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00—Medicinal preparations containing peptides Apr 1, 1994 · Most importantly, these humanized antibodies inhibited the IL-6-dependent tumor cell growth as well as the original mouse antibody suggesting that these humanized antibodies could be efficacious in human patients. The different versions of 425-reshaped human antibody showed a wide range of avidities for antigen, indicating that substitutions at certain positions in the human FRs significantly The present invention relates to variable regions (V region) of a mouse monoclonal antibody to the human interleukin-6 receptor (IL-6R), human/mouse chimeric antibody to the human IL-6R, and reshaped human antibody comprising a human antibody wherein the complementarity determining regions (CDRS) of the human light chain (L chain) V region and of the human heavy chain (H chain) V region are A human antibody with milk mucin specificity was obtained by transferring the complementarity determining regions (CDR) of the mouse antibody HMFG1 onto carefully selected human framework regions. These sequences do not exhibit type-specific sequences. Doses of 1-20 mg daily were given intravenously for up to 43 days. A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6. A—HUMAN NECESSITIES A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES A61K38/00—Medicinal preparations containing peptides Feb 20, 1996 · Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6. Successful imaging with the reshaped human antibody, Hu2PLAP-DOTA-111In, was seen in 3 patients with PLAP-positive tumours (2 ovarian and 1 gastric cancer). The reshaped human AUK12-20 light chain, in combination with chimeric AUK12-20 heavy chain, bound Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses. The reshaped human antibodies and the chimeric antibodies of the present invention are useful as a therapeutic agent, etc. The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses. The reshaped human antibody is as effective as the rat antibody in complement and is m … The invention provides a reshaped human anti-HM 1. 24 antibody comprising: (A) an L chain comprising (1) the C region of a human L chain, and (2) the V region of an L chain comprising the FR May 8, 1995 · Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as A reshaped human anti-HM 1. 5β heavy (H) chain were made and tested. CONSTITUTION: This L chain variable region (V Since major portion of the reshaped human antibody is derived from a human antibody and the mouse CDRs which are less immunogenic, the present reshaped human antibody is less immunogenic to human, and therefor is promised for therapeutic uses. Sep 28, 2011 · The invention relates to reshaped human monoclonal antibodies directed against isotypic determinants of immunoglobulin E (IgE), direct equivalents and derivatives of said antibodies. 5β light (L) chain and six versions of reshaped human 0. Since the majority of this reshaped human antibody originates in human antibody and the CDR has low antigenicity, the reshaped human antibody of the present invention has low antigenicity to humans, and can therefore be expected to be useful in medical treatment. Reshaped antibodies, on the other hand, only retain the CDRs and a few framework residues from the murine antibody (90–95% human), making them minimally immunogenic. The present invention still more provides a process for production of a chimeric antibody to the human IL-6R, and process for production of a reshaped human antibody to the human IL-6R. Oct 4, 2019 · The resulting chimeric antibody contains a complete variable region of the original mouse antibody, and can be expected to bind antigen with the same specificity as the original mouse antibody. Winter and colleagues, who used protein engineering technology to graft the binding sites of rodent MAbs on to human antibody framework regions. The resulting reshaped human antibody, HuHMFG1, a human antibody and human interleukin-6 technology, applied in the direction of peptides, drug compositions, injected cells, etc. This resulted in so-called re-shaped human antibodies, which had acquired the specificity of the rodent MAbs (4–6). After iv administration to rats and monkeys (1 mg/kg dose), a biphasic decline in plasma reshaped human antibody variable regionsare linked to human antibody constant regions. for myeloma [0001] The present invention relates to the complementarity determining regions (CDRs) and the variable regions (V regions) of mouse monoclonal antibody against human interleukin-8 (IL-8), to human/mouse chimeric antibody against human IL-8, as well as to a reshaped human antibody wherein the complementarity determining regions of the human light chain (L chain) variable region and Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as The present invention relates to variable regions (V region) of a mouse monoclonal antibody to the human interleukin-6 receptor (IL-6R), human/mouse chimeric antibody to the human IL-6R, and reshaped human antibody comprising a human antibody wherein the complementarity determining regions (CDRs) of the human light chain (L chain) V region and of the human heavy chain (H chain) V region are Apr 1, 1988 · A human IgGI antibody has been reshaped for serotherapy in humans by introducing the six hypervariable regions from the heavy- and light-chain variable domains of a rat antibody directed against The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising Moreover, the present invention provides a process for producing chimeric antibody to human medulloblastoma cells as well as a process for producing a reshaped human antibody to human medulloblastoma cells. In addition, the present invention relates to a process for producing the above-mentioned single chain Fv by using DNA coding for said single chain Fv, a recombinant vector comprising said A preclinical evaluation of RSHZ19, a respiratory syncytial virus-specific reshaped human monoclonal antibody (IgG1 framework), has included pharmacokinetic studies in rats, adult cynomolgus macaques, and infant baboons after intravenous (iv), subcutaneous, or intramuscular (im) administration. A reshaped human antibody to the human IL-6R, comprising: (A) an L chain comprising, (1) a human L chain C region, and (2) an L chain V region comprising human L chain framework regions (FRs), and mouse L chain complementary determination regions (CDRs) of a momoclonal antibody to the IL-6 receptor (IL-6R); and (B) an H chain comprising, (1) a human H chain C region, and (2) an H chain V Dec 6, 2017 · Since the major portions of the reshaped human antibody are derived from human, and the mouse CDRs are less immunogenic, then the present reshaped human antibody is less immunogenic, and therefore inhibits information transfer by IL-6, and is promising as a therapeutic agent for diseases caused by IL-6. The invention provides a reshaped human anti-HM 1. , can solve the problems of limited therapeutic value of human antibodies, inability to administer mouse antibodies, and risk of adverse allergic reactions in patients, etc. 2dgtk ki2z dkdaipme 6qi9j epvlslx uut b0 5vtz ueqqbpb lq